169 related articles for article (PubMed ID: 25097047)
1. Serum complements C3 and C4 in chronic HCV infection and their correlation with response to pegylated interferon and ribavirin treatment.
El-Fatah Fahmy Hanno A; Mohiedeen KM; Deghedy A; Sayed R
Arab J Gastroenterol; 2014 Jun; 15(2):58-62. PubMed ID: 25097047
[TBL] [Abstract][Full Text] [Related]
2. Effect of IFN-alpha on total haemolytic activity of CH50 complement system and C3, C4 levels in children with chronic hepatitis C.
Woźniakowska-Gesicka T; Wiśniewska-Ligier M; Kupś J
Med Sci Monit; 2001 May; 7 Suppl 1():202-6. PubMed ID: 12211720
[TBL] [Abstract][Full Text] [Related]
3. Chronic hepatitis C virus infection in renal transplant: treatment and outcome.
Sharma RK; Bansal SB; Gupta A; Gulati S; Kumar A; Prasad N
Clin Transplant; 2006; 20(6):677-83. PubMed ID: 17100715
[TBL] [Abstract][Full Text] [Related]
4. Viral interaction and responses in chronic hepatitis C and B coinfected patients with interferon-alpha plus ribavirin combination therapy.
Chuang WL; Dai CY; Chang WY; Lee LP; Lin ZY; Chen SC; Hsieh MY; Wang LY; Yu ML
Antivir Ther; 2005; 10(1):125-33. PubMed ID: 15751770
[TBL] [Abstract][Full Text] [Related]
5. Combination of interferon and ribavirin in chronic hepatitis C: re-treatment of nonresponders to interferon.
Di Bisceglie AM; Thompson J; Smith-Wilkaitis N; Brunt EM; Bacon BR
Hepatology; 2001 Mar; 33(3):704-7. PubMed ID: 11230751
[TBL] [Abstract][Full Text] [Related]
6. rs2230201 polymorphism may dictate complement C3 levels and response to treatment in chronic hepatitis C patients.
Chowdhury SJ; Karra VK; Gumma PK; Bharali R; Kar P
J Viral Hepat; 2015 Feb; 22(2):184-91. PubMed ID: 24995942
[TBL] [Abstract][Full Text] [Related]
7. Impact of pegylated interferon and ribavirin on morbidity and mortality in patients with chronic hepatitis C and normal aminotransferases in France.
Deuffic-Burban S; Babany G; Lonjon-Domanec I; Deltenre P; Canva-Delcambre V; Dharancy S; Louvet A; Roudot-Thoraval F; Mathurin P
Hepatology; 2009 Nov; 50(5):1351-9. PubMed ID: 19676130
[TBL] [Abstract][Full Text] [Related]
8. Complement C4 monitoring in the follow-up of chronic hepatitis C treatment.
Dumestre-Perard C; Ponard D; Drouet C; Leroy V; Zarski JP; Dutertre N; Colomb MG
Clin Exp Immunol; 2002 Jan; 127(1):131-6. PubMed ID: 11882043
[TBL] [Abstract][Full Text] [Related]
9. Serum complement C4 in chronic hepatitis C: correlation with histopathologic findings and disease activity.
Buğdaci MS; Karaca C; Alkim C; Kesıcı B; Bayraktar B; Sökmen M
Turk J Gastroenterol; 2012 Feb; 23(1):33-7. PubMed ID: 22505377
[TBL] [Abstract][Full Text] [Related]
10. The biological significance of serum complements C3 and C4 in HCV-related chronic liver diseases and hepatocellular carcinoma.
Ali OS; Abo-Shadi MA; Hammad LN
Egypt J Immunol; 2005; 12(2):91-9. PubMed ID: 17977214
[TBL] [Abstract][Full Text] [Related]
11. Association between Leptin and Complement in Hepatitis C Patients with Viral Clearance: Homeostasis of Metabolism and Immunity.
Chang ML; Kuo CJ; Huang HC; Chu YY; Chiu CT
PLoS One; 2016; 11(11):e0166712. PubMed ID: 27870883
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of human recombinant erythropoietin plus IFN-alpha in patients affected by chronic hepatitis C.
Di Fazio I; Motta M; Musumeci S; Neri S; Pistone G; Malaguarnera M
J Interferon Cytokine Res; 2004 Oct; 24(10):594-9. PubMed ID: 15626156
[TBL] [Abstract][Full Text] [Related]
13. Modifications of T-lymphocyte subsets before and during interferon and ribavirin treatment for chronic hepatitis C infection.
Neau-Cransac M; Foucher J; Ledinghen VD; Bernard PH; Legrand E; Lafon ME
Viral Immunol; 2005; 18(1):197-204. PubMed ID: 15802964
[TBL] [Abstract][Full Text] [Related]
14. Serum Soluble CD14 in Egyptian Patients with Chronic Hepatitis C: Its Relationship to Disease Progression and Response to Treatment.
Medhat E; Salama H; Fouad H; Abd El Haleem H; Said M; El-Nahaas SM; Omran D
J Interferon Cytokine Res; 2015 Jul; 35(7):563-8. PubMed ID: 25811314
[TBL] [Abstract][Full Text] [Related]
15. Treatment with ribavirin+alpha interferon in HCV chronic active hepatitis non-responders to interferon alone: preliminary results.
Scotto G; Ferrara S; Mangano A; Conte PE; Tantimonaco G
J Chemother; 1995 Feb; 7(1):58-61. PubMed ID: 7629562
[TBL] [Abstract][Full Text] [Related]
16. Role of complement component C4 in treatment response and disease progression in chronic hepatitis C patients.
Chowdhury SJ; Karra VK; Bharali R; Kar P
J Viral Hepat; 2015 Aug; 22(8):671-4. PubMed ID: 25573496
[TBL] [Abstract][Full Text] [Related]
17. Neurological manifestations of chronic hepatitis C.
Heckmann JG; Kayser C; Heuss D; Manger B; Blum HE; Neundörfer B
J Neurol; 1999 Jun; 246(6):486-91. PubMed ID: 10431776
[TBL] [Abstract][Full Text] [Related]
18. Levels of complement C3 and C4 components in Amerindians living in an area with high prevalence of tuberculosis.
Araujo Z; González N; de Cubeddu L; Ziegler RC; de Waard JH; Giampietro F; Garzaro D; Pujol FH; de Serrano NC; de Saboin AG
Mem Inst Oswaldo Cruz; 2006 Jun; 101(4):359-64. PubMed ID: 16951804
[TBL] [Abstract][Full Text] [Related]
19. Assessment of pro-inflammatory cytokines in sera of patients with hepatitis C virus infection before and after anti-viral therapy.
Alhetheel A; Albarrag A; Shakoor Z; Alswat K; Abdo A; Al-Hamoudi W
J Infect Dev Ctries; 2016 Oct; 10(10):1093-1098. PubMed ID: 27801372
[TBL] [Abstract][Full Text] [Related]
20. Should patients with chronic hepatitis C who have normal ALT levels be treated?
Russo MW; Brown RS
Curr Gastroenterol Rep; 2001 Feb; 3(1):49-53. PubMed ID: 11177694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
